Amarin Pharma Inc.
$405.1K 300 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Nova Eye, Inc.
Nova Eye, Inc. reported $404,701.44 across General Payments, Research, and Ownership to 474 physicians and teaching hospitals across 474 transactions.
- $404.7K Above-median payer
- All-tracks total
- 474 Above-median volume
- Transactions
- 474 Above-median reach
- Recipients
- +$152.8K
- General Payments vs PY2023
Nova Eye, Inc. reported $404,701.44 across all CMS Open Payments tracks (General + Research + Ownership) to 474 physicians and teaching hospitals in Program Year 2024 - ranking #818 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $404,701.44, averaging $853.80 per recipient.
Nova Eye, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
30/100
Total payments
F
14/100
Transaction volume
F
13/100
Physician reach
F
14/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer nova-eye-inc Nova Eye, Inc.
$404.7K · #818/1,925 · 0.0% industry · PY2024
- TOT $404.7K
- RANK #818
- SHARE 0.0%
- TXN 474
- RCP 474
- CAT 6
- GEN $404.7K
- ΔGEN +$152.8K
- TOP1 64.3%
- PY 2024
Volume peers
Nearest volume peer: Amarin Pharma Inc. ($405.1K)
Nova Eye, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Nova Eye, Inc.'s CMS-reported General Payments increased by $152.8K (+60.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOVA EYE, INC.PY2023: NOVA EYE, INC.PY2024: Nova Eye, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $251,855.26
- PY2024
- $404,701.44
What the Data Shows for Nova Eye, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Nova Eye, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
65 transactions worth $377.4K make "Consulting Fee" the top general-payment category in the 6-category breakdown below, 93.3% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Nova Eye, Inc. made 6 types of general payments. "Consulting Fee" is the largest category at $377.4K, 93.3% of General Payments.
Nova Eye, Inc. reports 6 general-payment categories - the top three are Consulting Fee (93.3%), Food and Beverage (5.1%), and Travel and Lodging (0.7%). The remaining 3 categories make up 0.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Nova Eye, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $377.4K | 65 | 93.3% |
| Food and Beverage | $20.6K | 401 | 5.1% |
| Travel and Lodging | $3.0K | 4 | 0.7% |
| Compensation for Faculty or Speaker (Medical Education) | $2.6K | 2 | 0.6% |
| Education | $1.1K | 1 | 0.3% |
| Compensation for Services Other Than Consulting | $90.95 | 1 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $312,294.27 (77.2%) of $404,701.44 in this company's General Payments records across 241 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Nova Eye, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Mahmoud Khaimi M.d.
$260,257.01 across 24 reported transactions
- 2
Mary Qiu
$26,903.48 across 11 reported transactions
- 3
Christine Marchetti Funke Md
$8,744.58 across 7 reported transactions
- 4
James Thomas Murphy Md
$8,264.20 across 3 reported transactions
- 5
Arsham Sheybani Md
$8,125.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Nova Eye, Inc. ranks #818 of 1,925 by total payments (top 42% by spend) but is notably more concentrated than that alone would suggest -- #437 of 1,838 by HHI (top 24% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Cochlear Ltd : $10.1K total payments, HHI 4273
- Change Healthcare Technologies, LLC : $89.9K total payments, HHI 4271
- Owens & Minor Distribution, Inc. : $316.70 total payments, HHI 4269
- Nucletron Operations B.V. : $108.4K total payments, HHI 4229
- Signature Orthopaedics USA Corp : $42.1K total payments, HHI 4228
- Clariance SAS : $73.8K total payments, HHI 4220
- Nova Eye, Inc. (this company) : $404.7K total payments, HHI 4216
- Lightscalpel Inc : $22.2K total payments, HHI 4194
- Dentium Co., Ltd : $56.4K total payments, HHI 4184
- Farallon Surgical, LLC : $288.4K total payments, HHI 4161
- Inova Diagnostics, Inc. : $8.3K total payments, HHI 4111
- CurveBeam LLC : $4.2K total payments, HHI 4090
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Nova Eye, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Nova Eye, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Nova Eye, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Ivoclar Vivadent, Inc.
$405.7K 1,041 recipients
Compare payment profiles
BlueRock Therapeutics LP
$405.9K 4 recipients
Compare payment profiles
Mizuho America, Inc.
$403.0K 57 recipients
Compare payment profiles
Onkos Surgical, Inc.
$402.3K 461 recipients
Compare payment profiles
Geistlich Pharma, North America, Inc.
$401.7K 2,543 recipients
Compare payment profiles
Put this to use
Nova Eye, Inc. ranks #818 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Nova Eye, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.